查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1416322

放射配體治療市場報告：2030 年趨勢、預測與競爭分析

Radioligand Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

放射配體治療的趨勢和預測

預計到 2030 年，全球放射配體治療市場將達到約 138 億美元，2024 年至 2030 年的複合年成長率為 5.0%。該市場的主要促進因素是癌症發病率的上升和對有效治療的高需求。全球放射配體治療市場的未來看起來充滿希望，醫院、診所和診斷中心市場充滿機會。

放射配體治療市場洞察

Lucintel 預測，由於癌症診斷的高需求，氟 18 在整個預測期內仍將是最大的細分市場。

由於久坐生活方式的普及和全球癌症病例的不斷增加，醫院將繼續成為該市場的最大細分市場。

由於專門的癌症醫院和研究中心的存在以及全部區域的癌症發病率增加，北美在預測期內可能仍然是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球放射配體治療市場預計將達到 138 億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球放射配體治療市場預計將以5.0%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要促進因素是癌症發生率的上升和對有效治療的高需求。

Q4.市場的主要細分市場是：

A4. 放射配體治療市場的未來前景廣闊，醫院、診所和診斷中心市場充滿機會。

Q5.市場的主要企業是：

A5. 主要的放射配體治療公司是：

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於癌症診斷的高需求，氟 18 在整個預測期內仍將是其最大的細分市場。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於專門的癌症醫院和研究中心的存在以及全部區域癌症發病率的增加，預計北美在預測期內仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球放射配體治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球放射配體治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按同位素分類的全球放射配體治療市場
    • 氟18
    • 鎵68
    • 鎦-177
    • 其他
  • 按目標受體分類的全球放射配體治療市場
    • 攝護腺特異性膜抗原
    • 生長抑制素受體
    • 表皮生長因子受體
    • 其他
  • 按適應症分類的全球放射配體治療市場
    • 攝護腺癌
    • 神經內分泌腫瘤
    • 乳癌
    • 其他
  • 按最終用途分類的全球放射配體治療市場
    • 醫院和診所
    • 診斷中心
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球放射配體治療市場按地區分類
  • 北美放射配體治療市場
  • 歐洲放射配體治療市場
  • 亞太地區放射配體治療市場
  • 其他地區放射配體治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按同位素分類的全球放射配體治療市場成長機會
    • 按目標受體分類的全球放射配體治療市場成長機會
    • 全球放射配體治療市場成長機會（按適應症）
    • 全球放射配體治療市場成長機會（依最終用途）
    • 按地區分類的全球放射配體治療市場成長機會
  • 全球放射配體治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球放射配體治療市場的產能擴張
    • 全球放射配體治療市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma
簡介目錄

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.

A more than 150-page report is developed to help in your business decisions.

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:

  • Fluorine - 18
  • Gallium - 68
  • Lutetium - 177
  • Others

Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:

  • Prostate-Specific Membrane Antigen
  • Somatostatin Receptor
  • Epidermal Growth Factor Receptor
  • Others

Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Breast Cancer
  • Others

Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Radioligand Therapy Market Insights

Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.

North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the radioligand therapy market size?

Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.

Q2. What is the growth forecast for radioligand therapy market?

Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the radioligand therapy market?

Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.

Q4. What are the major segments for radioligand therapy market?

Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.

Q5. Who are the key radioligand therapy market companies?

Answer: Some of the key radioligand therapy companies are as follows:

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Q6. Which radioligand therapy market segment will be the largest in future?

Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radioligand Therapy Market by Isotope
    • 3.3.1: Fluorine - 18
    • 3.3.2: Gallium - 68
    • 3.3.3: Lutetium - 177
    • 3.3.4: Others
  • 3.4: Global Radioligand Therapy Market by Targeted Receptor
    • 3.4.1: Prostate-specific Membrane Antigen
    • 3.4.2: Somatostatin Receptor
    • 3.4.3: Epidermal Growth Factor Receptor
    • 3.4.4: Others
  • 3.5: Global Radioligand Therapy Market by Indication
    • 3.5.1: Prostate Cancer
    • 3.5.2: Neuroendocrine Tumors
    • 3.5.3: Breast Cancer
    • 3.5.4: Others
  • 3.6: Global Radioligand Therapy Market by End Use
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Diagnostic Centers
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radioligand Therapy Market by Region
  • 4.2: North American Radioligand Therapy Market
    • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.3: European Radioligand Therapy Market
    • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.4: APAC Radioligand Therapy Market
    • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.5: ROW Radioligand Therapy Market
    • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
    • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
    • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
    • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
    • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
  • 6.2: Emerging Trends in the Global Radioligand Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: POINT Biopharma Global
  • 7.3: Molecular Partners
  • 7.4: Telix Pharmaceuticals
  • 7.5: Fusion Pharma
  • 7.6: Lantheus Holdings
  • 7.7: Curium
  • 7.8: Precrix
  • 7.9: Orano
  • 7.10: Artios Pharma